BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 10, 2015
 |  BioCentury  |  Emerging Company Profile

New tac for modifying PAH

Targeting BMPRII signaling could give Selten first disease-modifying PAH therapy

Selten Pharma Inc. is developing a new formulation of the generic immunosuppressive drug tacrolimus that activates the BMPRII pathway and could prevent or even reverse the deleterious vascular remodeling seen with pulmonary arterial hypertension.

In PAH, increased smooth muscle cell proliferation and resistance to apoptosis in pulmonary vasculature results in narrowing and obstruction of the pulmonary arteries, hypertension, right ventricular hypertrophy and eventual death.

The standard of care includes four classes of drugs that all work by promoting a direct or indirect vasodilator effect on the pulmonary artery to alleviate disease symptoms. No approved therapies treat the underlying inflammatory and fibrotic elements of the disease.

Bone morphogenetic protein receptor type II (BMPRII) inhibits the proliferation of vascular smooth muscle cells and promotes the survival of pulmonary arterial endothelial cells, preventing arterial damage and inflammation. It also inhibits pulmonary arterial proliferation, preventing arteries from being closed off.

The discovery that BMPRII is mutated in a genetic...

Read the full 802 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >